MEDICAMEN Biotech Limited

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

To,

Date: 17.01.2022

BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Code-531146

NSE Code: MEDICAMEQ

Sub: Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended on December 31, 2021

Dear Sir / Madam

This is to inform that the details of securities dematerialized / rematerialized during the quarter ended December 31, 2021, as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 have been furnished by our Registrar and Share Transfer Agent to all the Stock Exchanges, where the shares of the Company are listed (copy enclosed).

We hereby confirm and certify that:

(a) The securities comprised in the said certificates(s) have been listed on the stock exchanges or exchanges were the earlier issued securities were listed; and

(b) The certificates have been mutilated and cancelled after due verification and the name of the depository has been substituted in our records as the registered owner within 30 days of its receipt.

Thanking you

Yours truly

For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS 44157

Link Intime India Pvt. Ltd.
Noble Heights , 1st Floor ,
Plot No. NH 2 , LSC, C-1 Block ,
Near Savitri Market, Janakpuri,
New Delhi-110058
Phone : 011-49411000
Fax : 011-41410591
E-mail : delhi@linkintime.co.in

January 7, 2022

Company Secretary
Medicamen Biotech Ltd.
1506, Chiranjiv Tower
43, Nehru Place
New Delhi-110019

Subject: Confirmation Certificate in the matter of Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Dear Sir,

In reference to the above captioned regulation, we hereby confirm that the securities received from the depository participants for dematerialisation during the quarter ended 31st December, 2021, were confirmed (accepted/rejected) to the depositories by us and that securities comprised in the said certificates have been listed on the stock exchanges where the earlier issued securities are listed.

SEBI vide its Circular No. SEBI/HO/MIRSD/RTAMB/P/CIR/2021/558 dated April 29, 2021 in view of the Covid-19 situation had provided relaxation in adherence to the prescribed timelines which included the processing of the demat requests by the Issuer Company/RTA. The relaxation was provided up to July 31, 2021. We have been informed that in view of the surge in volumes in Demat Requests, Update Requests, Investor correspondence etc. from July 2021 onwards, Registrars Association of India (RAIN) has requested SEBI for doubling the timelines for all activities with prescribed time limits for a limited period up to 31st March 2022. RAIN is yet to receive confirmation to the request from SEBI. We hereby also confirm that the security certificates received for dematerialisation have been confirmed/rejected and the security certificates received were mutilated and cancelled after due verification by the depository participant and the name of the depositories have been substituted in the register of members as the registered owner within 15 days. We request you to kindly take note of the above in your records.

We request you to kindly take note of the above in your records.

Thanking You,

Yours faithfully,
For Link Intime India Pvt. Ltd

Swapan Kumar Naskar
Associate Vice-President & Hed (Delhi Branch)

Medicamen Biotech Limited